AOD 9604 is a synthetic peptide derived from a small section of human growth hormone that targets fat metabolism without the broader hormonal effects of growth hormone itself. It works primarily by stimulating the breakdown of stored fat and increasing energy expenditure, mimicking only the fat-burning portion of growth hormone’s activity. Despite generating significant interest in weight loss and wellness circles, its clinical story is more complicated than most marketing suggests.
A Fragment of Growth Hormone
Human growth hormone is a large protein with many functions, from building muscle to regulating blood sugar to breaking down fat. Researchers identified that a specific 16-amino-acid stretch near the tail end of the molecule, amino acids 177 through 191, was responsible for much of its fat-burning activity. AOD 9604 is a synthetic copy of that fragment with one small modification: an added tyrosine amino acid at the beginning, which stabilizes the peptide and makes it functional on its own.
The key advantage of isolating this fragment is selectivity. Full-length growth hormone affects nearly every tissue in the body and, with chronic use, can cause insulin resistance, joint pain, and increased blood sugar. AOD 9604 was designed to retain the fat-specific effects while leaving everything else behind. Animal studies confirmed this: chronic treatment with AOD 9604 showed no adverse effect on insulin sensitivity, in direct contrast to treatment with intact growth hormone.
How It Affects Fat Cells
AOD 9604 promotes fat loss through two related pathways: it stimulates lipolysis (the breakdown of stored fat into usable energy) and it increases overall fat oxidation and energy expenditure. The precise mechanism is still not fully mapped, but research in obese mice has clarified several pieces of the puzzle.
One important finding involves a receptor on fat cells called the beta-3 adrenergic receptor. This receptor plays a major role in triggering fat breakdown. In obese mice, expression of this receptor is suppressed compared to lean mice. Both full growth hormone and AOD 9604 restored expression of this receptor back to levels comparable to those seen in lean animals. This upregulation likely makes fat cells more responsive to the body’s normal fat-burning signals over time.
Interestingly, though, the peptide’s fat-burning effects don’t depend entirely on this receptor. When researchers tested AOD 9604 in mice genetically engineered to lack the beta-3 adrenergic receptor entirely, the peptide still increased energy expenditure and fat oxidation. This means AOD 9604 also works through at least one additional, independent pathway that scientists haven’t yet pinpointed. The result is a compound that enhances fat metabolism through multiple routes rather than a single switch.
What Separates It From Growth Hormone
The distinction between AOD 9604 and full growth hormone matters because growth hormone’s side effects are one of the main reasons it isn’t used as a weight loss drug. Growth hormone pushes the body toward insulin resistance, essentially making cells less responsive to insulin and raising blood sugar. Over time, this can increase the risk of type 2 diabetes. It also stimulates growth in tissues beyond fat, which raises concerns about joint problems and, theoretically, tumor growth.
AOD 9604 bypasses these issues because it contains none of the structural regions responsible for growth hormone’s effects on insulin, muscle, bone, or organ growth. In studies using euglycemic clamp techniques (a precise way of measuring how well the body responds to insulin), animals treated chronically with AOD 9604 showed no change in insulin sensitivity. This is what made the peptide attractive as a potential obesity drug: fat-specific action without the metabolic fallout.
Clinical Trials and Their Results
AOD 9604 moved through early human trials with promising but ultimately disappointing results. In a 12-week randomized clinical trial, subjects taking 1 mg per day orally lost an average of 2.6 kg, compared to 0.8 kg in the placebo group. That difference, roughly 4 pounds over three months, was statistically significant but modest.
The larger test came next. A 24-week Phase IIb trial enrolled 536 subjects, and the peptide failed to produce significant weight loss compared to placebo at that scale. The drug’s developer, Metabolic Pharmaceuticals, terminated development in 2007. The safety profile remained clean throughout: in the 536-subject trial, tolerability was described as “excellent with no evidence of any difference from placebo.” But a weight loss drug that doesn’t reliably produce weight loss has no path to approval.
Despite this failure as a standalone oral obesity drug, AOD 9604 has continued to circulate in compounding pharmacies and wellness clinics, typically as a subcutaneous injection. A search of the FDA’s adverse event reporting system through January 2024 turned up zero reports associated with AOD 9604, and a review of real-world data covering nearly 159,000 prescriptions found no serious adverse events directly attributable to the compound. The safety record is unusually clean, even if the efficacy record is underwhelming for weight loss.
Joint and Cartilage Research
More recently, AOD 9604 has attracted attention for a completely different application: joint health. In a rabbit model of knee osteoarthritis, intra-articular injections of AOD 9604 enhanced cartilage regeneration. This research is still in early stages, using animal models rather than human trials, but it has positioned AOD 9604 alongside other peptides being investigated for bone and joint repair.
The connection between a fat-burning peptide and cartilage repair isn’t as strange as it sounds. Growth hormone itself plays a role in tissue repair throughout the body, and isolated fragments of the molecule may retain some of those regenerative properties even when they no longer trigger the full hormonal cascade. Researchers have tested AOD 9604 delivered by injection directly into joints, as well as in combination with hyaluronic acid, a substance already used in joint injections. The combination appeared to offer additional benefit in the rabbit model, though translating animal cartilage studies to human joints is notoriously difficult.
Regulatory Status
AOD 9604 occupies a gray area in U.S. regulation. It is not FDA-approved as a drug for any indication. It does not hold Generally Recognized as Safe (GRAS) status for use in food or supplements, and the FDA’s GRAS Notice Inventory contains no entry for it. It is available through compounding pharmacies, which operate under different rules than pharmaceutical manufacturers, and it has been the subject of FDA advisory committee discussions about whether it should remain available for compounding.
This means that if you encounter AOD 9604, it is coming from a compounding pharmacy filling a prescription, not from a regulated pharmaceutical product that has passed efficacy trials. The safety data from nearly 159,000 dispensed prescriptions is reassuring, but the lack of proven efficacy for any specific condition in humans is the central limitation. The peptide reliably stimulates fat metabolism in animal models and shows a favorable safety profile in humans, but the gap between those two facts and a proven clinical benefit remains open.